NCT07366411Not yet recruitingPhase 2
taVNS on Functional Mobility in People With DP
Transcutaneous Auricular Vagus Nerve Stimulation on Functional Mobility in People With Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
Parkinson's disease (PD) is characterized by motor impairments such as bradykinesia accompanied by resting tremor and/or rigidity. As PD progresses due to its neurodegenerative nature, complementary strategies must be developed to optimize its effects. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a strategy for controlling the symptoms of the disease. Nevertheless, the efficacy of this approach in managing PD remains to be elucidated. The objective of the present study is to investigate and compare the effects of transcutaneous vagus nerve stimulation (taVNS) and sham taVNS on functional mobility, which is the primary outcome and will be assessed using the Timed Up and Go test. The following tests will be used to evaluate the secondary outcomes: the miniBESTest and the Biodex Balance System (balance), the MDS-UPDRS and the Five-Time Sit-to-Stand Test (motor function), the FOG-Q (freezing of gait), the 10-Meter Walk Test (gait speed), the PGIC (perception of change), and the recording of adverse events. The volunteers will be divided into two groups: one group will receive taVNS in conjunction with physical therapy, while the other group will receive a sham taVNS in conjunction with physical therapy. To assess the effect of therapy, the efficacy of taVNS in enhancing the effects of physical therapy on the functional mobility of people with PD will be evaluated.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 1 Dec 2025
- Start date
- 15 Feb 2026
- Primary completion date
- 15 Mar 2027
- Lead sponsor
- Universidade Federal de Pernambuco
- Diseases
- Parkinson disease
- NCT number
- NCT07366411
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 15 Feb 2026 to the primary completion date, 15 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous surgical procedure for PD.
Other illness
- other neurological disorders, postural hypotension, vestibular, musculoskeletal, or visual disorders that compromise performance in the proposed tests;
- other osteomyoarticular diseases in the lower limbs that interfere with performance and locomotion;
Other
- Montreal Cognitive Assessment (MoCA) score lower than 21 points;
Who the study is looking for
- clinical diagnosis of PD provided by a neurologist;
- undergoing regular antiparkinsonian drug treatment (at least three months of regular and stable use);
- aged 40 years or older;
- with a Hoehn \& Yahr stage of 2.5 to 4.
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universidade Federal de Pernambuco Coordinator of this site? Confirm its status | Recife | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.